|
|
Blood, 15 April 2005, Vol. 105, No. 8, pp. 3011-3018.
Prepublished online as a Blood First Edition Paper on December 16, 2004; DOI 10.1182/blood-2004-10-4072.
Previous Article | Table of Contents | Next Article 
PLENARY PAPERS
Differential expression of SHIP1 in CD56bright and CD56dim NK cells provides a molecular basis for distinct functional responses to monokine costimulation
Rossana Trotta,
Robin Parihar,
Jianhua Yu,
Brian Becknell,
Jeffrey Allard, II,
Jing Wen,
Wei Ding,
Hsiaoyin Mao,
Susheela Tridandapani,
William E. Carson, and
Michael A. Caligiuri
From the Division of Human Cancer Genetics, Department of Molecular Virology, Immunology, and Medical Genetics; Medical Scientific Program, Integrated Biomedical Graduate Program, College of Medicine and Public Health; Division of Pulmonary and Critical Care, Department of Internal Medicine; The Comprehensive Cancer Center, The Ohio State University; Division of Surgical Oncology, Department of Surgery; and Division of Hematology/Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH.
Monocyte cytokines (ie, monokines) induce natural killer (NK) cells to produce interferon- (IFN- ), which is critical for monocyte clearance of infectious pathogens and tumor surveillance. Human CD56bright NK cells produce far more IFN- in response to monokines than do CD56dim NK cells. The kinases and phosphatases involved in regulating IFN- production by monokine-activated NK cells are not clearly identified. SHIP1 is a 5' inositol phosphatase that dephosphorylates the phosphatidylinositol-3 kinase (PI-3K) product PI3,4,5P3. Here, we show that constitutive expression of SHIP1 is distinctly lower in CD56bright NK cells compared with CD56dim NK cells, suggesting it could be an important negative regulator of IFN- production in monokine-activated NK cells. Indeed, overexpression of SHIP1 in CD56bright NK cells followed by monokine activation substantially lowered IFN- production. This effect was not seen when NK cells were infected with a SHIP1 mutant containing an inactive catalytic domain. Finally, NK cells in SHIP1/ mice produced more IFN- in response to monokines in vivo than did NK cells from wild-type mice. Collectively, these results demonstrate that SHIP1 negatively regulates monokine-induced NK cell IFN- production in vitro and in vivo and provide the first molecular explanation for an important functional distinction observed between CD56bright and CD56dim human NK subsets.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Article in Blood Online:
-
NK cell cytokine secretion regulated by SHIP1
- Jerome Ritz
Blood 2005 105: 3003.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
S. V. Kondadasula, J. M. Roda, R. Parihar, J. Yu, A. Lehman, M. A. Caligiuri, S. Tridandapani, R. W. Burry, and W. E. Carson III
Colocalization of the IL-12 receptor and Fc{gamma}RIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-{gamma}
Blood,
April 15, 2008;
111(8):
4173 - 4183.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Schierloh, N. Yokobori, M. Aleman, V. Landoni, L. Geffner, R. M. Musella, J. Castagnino, M. Baldini, E. Abbate, S. S. de la Barrera, et al.
Mycobacterium tuberculosis-Induced Gamma Interferon Production by Natural Killer Cells Requires Cross Talk with Antigen-Presenting Cells Involving Toll-Like Receptors 2 and 4 and the Mannose Receptor in Tuberculous Pleurisy
Infect. Immun.,
November 1, 2007;
75(11):
5325 - 5337.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Trotta, D. Ciarlariello, J. D. Col, J. Allard II, P. Neviani, R. Santhanam, H. Mao, B. Becknell, J. Yu, A. K. Ferketich, et al.
The PP2A inhibitor SET regulates natural killer cell IFN-{gamma} production
J. Exp. Med.,
October 1, 2007;
204(10):
2397 - 2405.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. G. Quaranta, A. Napolitano, M. Sanchez, L. Giordani, B. Mattioli, and M. Viora
HIV-1 Nef impairs the dynamic of DC/NK crosstalk: different outcome of CD56dim and CD56bright NK cell subsets
FASEB J,
August 1, 2007;
21(10):
2323 - 2334.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W.-C. Hsieh, Y. Chang, M.-C. Hsu, B.-S. Lan, G.-C. Hsiao, H.-C. Chuang, and I.-J. Su
Emergence of Anti-Red Blood Cell Antibodies Triggers Red Cell Phagocytosis by Activated Macrophages in a Rabbit Model of Epstein-Barr Virus-Associated Hemophagocytic Syndrome
Am. J. Pathol.,
May 1, 2007;
170(5):
1629 - 1639.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Tessmer, C. Fugere, F. Stevenaert, O. V. Naidenko, H. J. Chong, G. Leclercq, and L. Brossay
KLRG1 binds cadherins and preferentially associates with SHIP-1
Int. Immunol.,
April 1, 2007;
19(4):
391 - 400.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Becknell, T. L. Hughes, A. G. Freud, B. W. Blaser, J. Yu, R. Trotta, H. C. Mao, M. L. Caligiuri de Jesus, M. Alghothani, D. M. Benson Jr, et al.
Hlx homeobox transcription factor negatively regulates interferon-{gamma} production in monokine-activated natural killer cells
Blood,
March 15, 2007;
109(6):
2481 - 2487.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Fulci, L. Breymann, D. Gianni, K. Kurozomi, S. S. Rhee, J. Yu, B. Kaur, D. N. Louis, R. Weissleder, M. A. Caligiuri, et al.
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses
PNAS,
August 22, 2006;
103(34):
12873 - 12878.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. P. Ganesan, T. Joshi, H. Fang, V. K. Kutala, J. Roda, R. Trotta, A. Lehman, P. Kuppusamy, J. C. Byrd, W. E. Carson, et al.
Fc{gamma}R-induced production of superoxide and inflammatory cytokines is differentially regulated by SHIP through its influence on PI3K and/or Ras/Erk pathways
Blood,
July 15, 2006;
108(2):
718 - 725.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. E. Schade, J. J. Powers, M. W. Wlodarski, and J. P. Maciejewski
Phosphatidylinositol-3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis
Blood,
June 15, 2006;
107(12):
4834 - 4840.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. G. Freud, A. Yokohama, B. Becknell, M. T. Lee, H. C. Mao, A. K. Ferketich, and M. A. Caligiuri
Evidence for discrete stages of human natural killer cell differentiation in vivo
J. Exp. Med.,
April 17, 2006;
203(4):
1033 - 1043.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Bielekova, M. Catalfamo, S. Reichert-Scrivner, A. Packer, M. Cerna, T. A. Waldmann, H. McFarland, P. A. Henkart, and R. Martin
Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2R{alpha}-targeted therapy (daclizumab) in multiple sclerosis
PNAS,
April 11, 2006;
103(15):
5941 - 5946.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Parihar, R. Trotta, J. M. Roda, A. K. Ferketich, S. Tridandapani, M. A. Caligiuri, and W. E. Carson III
Src Homology 2-Containing Inositol 5'-Phosphatase 1 Negatively Regulates IFN-{gamma} Production by Natural Killer Cells Stimulated with Antibody-Coated Tumor Cells and Interleukin-12
Cancer Res.,
October 1, 2005;
65(19):
9099 - 9107.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Vely and E. Vivier
Natural Killer Cell Receptor Signaling Pathway
Sci. Signal.,
July 12, 2005;
2005(292):
cm6 - cm6.
[Abstract]
[Full Text]
[PDF]
|
 |
|
| |